Alumni Ventures
Analysis of 179 preclinical biotech financings (2024–mid-2026) identifies four critical dimensions—CEO experience, lead investor strength, technology origin, and translational stage—that determine funding success. Companies strong in three or four dimensions raise 5–25x more capital at similar valuations, establishing a clear 'Trifecta+' funding archetype.
Topics: Biotech & Life Sciences · Venture Capital & Startups
SandHill indexes 800+ venture capital blogs and newsletters and sends the best of them every Sunday. Browse the sources · browse by topic · read the blog.
Suggest a blog or newsletter for the SandHill index. We track the RSS feed and feature the best pieces in the weekly digest.
The latest theses & analyses from 800+ venture investors, curated into one email. Join 5,000+ investors, founders and LPs.